Chiasso, Switzerland, December 4th, 2024 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized for the third time as one of the best places to work in Switzerland...

Chiasso, Switzerland, November 6th, 2023 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized for the second time as one of the best places to work in Switzerlan...

Chiasso, Switzerland and Reading, England, October 4th, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are delighted to announce the official launch of Sapropterin Dihydrochloride (“Sapropterin”) in the United Kingdom. Sa...

Chiasso, Switzerland, July 3rd, 2023 – Dipharma SA (“Dipharma”) today announced that its product Sapropterin Dipharma is now available in main European Countries and in Switzerland. Sapropterin Dipharma is available in the form of soluble ta...

Chiasso, Switzerland and Reading, England, June 27, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are pleased to announce that the Medicines and Healthcare Products Regulatory Agency (“MHRA”) has granted Marketing Authorization for ...

Princeton, NJ and Chiasso, Switzerland, May 31 st , 2023 – Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug applica...

Chiasso, September 15th, 2022 | Dipharma SA, a specialty pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized as one of the best places to work for in Switzerland. During the ass...

Rosemont, PA and Chiasso, Switzerland, June 21st, 2022 – Analog Pharma (“Analog”) and Dipharma S.A. (“Dipharma”) today announced that their nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug ...

Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen the largely unexplored rare diseases generics space and the opportunities in metabolic diseases. Marc-Olivier Geinoz – CEO, Dipharma SA Dipharma SA is a Swiss specialty pha...

Chiasso, Switzerland, February 16th, 2021 – Swiss-based Dipharma S.A. (“Dipharma”) today announced that its proprietary product Miglustat Dipharma 100 mg capsules is now available in Switzerland. Miglustat Dipharma, a generic equivalent to Actelio...

Chiasso, Switzerland, February 20th, 2019 – – Dipharma S.A. (“Dipharma”) today announced that the European Commission has granted Marketing Authorization of its generic Miglustat. This authorization comes after CHMP positive opinion last December ...

The first generic version of Miglustat is now approved in the U.S. Lyndhurst, N.J. and Chiasso, Switzerland. April 18th, 2018 – Amerigen Pharmaceuticals Limited (“Amerigen”) and Dipharma S.A. (“Dipharma”) today announced that Amerigen’s Abbr...

The first stable capsule formulation of Nitisinone for the treatment of hereditary Tyrosinemia type-1 (HT-1) is now under marketing authorization (MA) evaluation in the EU. Chiasso, Switzerland, February 23rd, 2017 – Dipharma S.A. announces the va...

First drug now registered and commercially available in the Republic of South Korea for the treatment of Hyperphenylalaninemia (HPA) due to Phenylketonuria (PKU). Chiasso, Switzerland and Seoul, South Korea, February 3rd, 2017 – Dipharma S.A. and ...